A citation-based method for searching scientific literature

Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy, Michael J Koren, Norman E Lepor, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, John J P Kastelein. N Engl J Med 2015
Times Cited: 1271







List of co-cited articles
863 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
70

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
55

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jennifer Robinson, Christie M Ballantyne, Ransi Somaratne, Jason Legg, Scott M Wasserman,[...]. N Engl J Med 2015
43

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
43

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
538
22

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
22

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Christopher P Cannon, Bertrand Cariou, Dirk Blom, James M McKenney, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M Colhoun. Eur Heart J 2015
279
21

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
277
20

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Jonathan C Cohen, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs. N Engl J Med 2006
18

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, Fernando Civeira, Marcus Flather, Robert J Glynn, Jean Gregoire, J Wouter Jukema,[...]. N Engl J Med 2017
381
17

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
17

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
17

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Dean J Kereiakes, Jennifer G Robinson, Christopher P Cannon, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M Colhoun. Am Heart J 2015
244
17

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
John J P Kastelein, Henry N Ginsberg, Gisle Langslet, G Kees Hovingh, Richard Ceska, Robert Dufour, Dirk Blom, Fernando Civeira, Michel Krempf, Christelle Lorenzato,[...]. Eur Heart J 2015
355
17

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
251
16

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren,[...]. N Engl J Med 2017
447
15

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, Gaetano M De Ferrari, Zbigniew A Gaciong, Richard Ceska, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele,[...]. Lancet 2017
316
15

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
14

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Dirk J Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska, Eli Roth, Michael J Koren, Christie M Ballantyne,[...]. N Engl J Med 2014
469
14

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, R Scott Wright, Peter L J Wijngaard, Danielle Curcio, Mark J Jaros, Lawrence A Leiter,[...]. N Engl J Med 2020
182
14

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Narimon Honarpour, Dirk J Blom, G Kees Hovingh, Feng Xu, Rob Scott, Scott M Wasserman, Evan A Stein. Lancet 2015
482
13

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Paul M Ridker, Jean-Claude Tardif, Pierre Amarenco, William Duggan, Robert J Glynn, J Wouter Jukema, John J P Kastelein, Albert M Kim, Wolfgang Koenig, Steven Nissen,[...]. N Engl J Med 2017
211
12

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Patrick M Moriarty, Paul D Thompson, Christopher P Cannon, John R Guyton, Jean Bergeron, Franklin J Zieve, Eric Bruckert, Terry A Jacobson, Stephen L Kopecky, Marie T Baccara-Dinet,[...]. J Clin Lipidol 2015
301
12

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
Eli M Roth, Patrick M Moriarty, Jean Bergeron, Gisle Langslet, Garen Manvelian, Jian Zhao, Marie T Baccara-Dinet, Daniel J Rader. Atherosclerosis 2016
75
16

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Nabil G Seidah, Suzanne Benjannet, Louise Wickham, Jadwiga Marcinkiewicz, Stephanie Belanger Jasmin, Stefano Stifani, Ajoy Basak, Annik Prat, Michel Chretien. Proc Natl Acad Sci U S A 2003
817
11

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis,[...]. Lancet Diabetes Endocrinol 2017
298
10

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Christine Landlinger, Marianne G Pouwer, Claudia Juno, José W A van der Hoorn, Elsbet J Pieterman, J Wouter Jukema, Guenther Staffler, Hans M G Princen, Gergana Galabova. Eur Heart J 2017
126
10

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
Michael J Koren, Pernille Lundqvist, Michael Bolognese, Joel M Neutel, Maria Laura Monsalvo, Jingyuan Yang, Jae B Kim, Rob Scott, Scott M Wasserman, Harold Bays. J Am Coll Cardiol 2014
280
10

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, Jonathan Fialkow, Joel M Neutel, David Ramstad, Ransi Somaratne, Jason C Legg, Patric Nelson, Rob Scott,[...]. JAMA 2014
341
10

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
Michael J Koren, Marc S Sabatine, Robert P Giugliano, Gisle Langslet, Stephen D Wiviott, Andrea Ruzza, Yuhui Ma, Andrew W Hamer, Scott M Wasserman, Frederick J Raal. J Am Coll Cardiol 2019
62
16

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
Jonathan Cohen, Alexander Pertsemlidis, Ingrid K Kotowski, Randall Graham, Christine Kim Garcia, Helen H Hobbs. Nat Genet 2005
910
10

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Henry N Ginsberg, Daniel J Rader, Frederick J Raal, John R Guyton, Marie T Baccara-Dinet, Christelle Lorenzato, Robert Pordy, Erik Stroes. Cardiovasc Drugs Ther 2016
126
10

Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
Gergana Galabova, Sylvia Brunner, Gabriele Winsauer, Claudia Juno, Bettina Wanko, Andreas Mairhofer, Petra Lührs, Achim Schneeberger, Arne von Bonin, Frank Mattner,[...]. PLoS One 2014
87
10

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. J Am Coll Cardiol 2019
657
9

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Brian A Ference, Jennifer G Robinson, Robert D Brook, Alberico L Catapano, M John Chapman, David R Neff, Szilard Voros, Robert P Giugliano, George Davey Smith, Sergio Fazio,[...]. N Engl J Med 2016
412
9

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. J Am Coll Cardiol 2019
946
9

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.
Jennifer G Robinson, Robert S Rosenson, Michel Farnier, Umesh Chaudhari, William J Sasiela, Laurence Merlet, Kathryn Miller, John J P Kastelein. J Am Coll Cardiol 2017
123
9

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Harold Bays, Daniel Gaudet, Robert Weiss, Juan Lima Ruiz, Gerald F Watts, Ioanna Gouni-Berthold, Jennifer Robinson, Jian Zhao, Corinne Hanotin, Stephen Donahue. J Clin Endocrinol Metab 2015
168
9

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Kausik K Ray, Harold E Bays, Alberico L Catapano, Narendra D Lalwani, LeAnne T Bloedon, Lulu R Sterling, Paula L Robinson, Christie M Ballantyne. N Engl J Med 2019
249
9

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Evan A Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders G Olsson, David Sullivan,[...]. Lancet 2015
476
9

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
9

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
9

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Eur Heart J 2016
9

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Eliano P Navarese, Jennifer G Robinson, Mariusz Kowalewski, Michalina Kolodziejczak, Felicita Andreotti, Kevin Bliden, Udaya Tantry, Jacek Kubica, Paolo Raggi, Paul A Gurbel. JAMA 2018
210
9

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouni-Berthold, KyungAh Im, Armando Lira Pineda, Scott M Wasserman, Richard Češka,[...]. Circulation 2019
287
9

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Eliano Pio Navarese, Michalina Kolodziejczak, Volker Schulze, Paul A Gurbel, Udaya Tantry, Yingfeng Lin, Maximilian Brockmeyer, David E Kandzari, Julia M Kubica, Ralph B D'Agostino,[...]. Ann Intern Med 2015
297
8

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham,[...]. Eur Heart J 2018
140
8

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
Børge G Nordestgaard, M John Chapman, Steve E Humphries, Henry N Ginsberg, Luis Masana, Olivier S Descamps, Olov Wiklund, Robert A Hegele, Frederick J Raal, Joep C Defesche,[...]. Eur Heart J 2013
8

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Michel Farnier, Peter Jones, Randall Severance, Maurizio Averna, Elisabeth Steinhagen-Thiessen, Helen M Colhoun, Yunling Du, Corinne Hanotin, Stephen Donahue. Atherosclerosis 2016
142
8

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
Eliano P Navarese, Michalina Kolodziejczak, Max-Paul Winter, Arman Alimohammadi, Irene M Lang, Antonino Buffon, Gregory Yh Lip, Jolanta M Siller-Matula. Int J Cardiol 2017
57
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.